Ask AI
ProCE Banner Series

HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape

The NSCLC antibody–drug conjugate (ADC) landscape has entered a new phase: the critical educational need is no longer simply awareness of HER2- and TROP2-directed therapies, but the ability to apply them with precision, sequencing discipline, and proactive toxicity management. In this symposium, held in conjunction with IASLC/ASCO 2026 North America Conference on Lung Cancer, faculty will guide learners through an in-depth discussion focused on practical integration of HER2- and TROP2-directed ADCs into NSCLC care, including patient selection, treatment sequencing, interpretation of emerging evidence, and proactive toxicity management.

  AMA
Who Should Attend

This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

All Events

HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape

Upcoming Events

December

05

2026

11:45 AM - 1:00 PM Mountain Time (MT)

In-person

Grand Hyatt Scottsdale Resort, 7500 E. Doubletree Ranch Road, Scottsdale, Arizona 85258

12:00 PM - 1:00 PM Mountain Time (MT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in the evidence-based integration of HER2- and TROP2-directed ADCs in patients with NSCLC, with an emphasis on patient selection, treatment sequencing, interpretation of emerging evidence, and proactive management of ADC-associated toxicities.

Target Audience
This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Differentiate HER2 mutation, HER2 tyrosine kinase domain mutation, HER2 IHC 3+ overexpression, and HER2 amplification in NSCLC, and apply these distinctions to biomarker interpretation, treatment selection, sequencing, and clinical-trial referral

  • Select and sequence HER2-directed ADCs, HER2-directed TKIs, chemotherapy/immunotherapy, and clinical-trial strategies for patients with HER2-mutated advanced NSCLC based on biomarker profile, prior therapy, CNS involvement, disease tempo, pulmonary risk, access, and patient preference

  • Integrate TROP2-directed ADC therapy into evidence-based treatment pathways for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy, while distinguishing current approved use from investigational earlier-line, AGA-negative, PD-L1–defined, and biomarker-enriched strategies

  • Apply practical, multidisciplinary workflows to interpret emerging NSCLC ADC data and manage ADC-associated toxicities, including ILD/pneumonitis, ocular toxicity, stomatitis, gastrointestinal toxicity, fatigue, and myelosuppression, using appropriate treatment interruption, referral, rechallenge, and discontinuation strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Title: A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191